News List

Alkem Labs to market Stempeutics\' osteoarthritis stem cell therapy


Alkem will get the exclusive marketing rights for Stempeucel and Stempeutics will manufacture and supply the product.

By Team ABLE

Alkem Laboratories has signed an exclusive licensing deal to market the osteoarthritis (OA) therapy Stempeucel, manufactured by Stempeutics Research.

As per the agreement, Alkem will get the exclusive marketing rights for Stempeucel and Stempeutics will manufacture and supply the product. Although the financial details of the deal were not disclosed, it is believed that an upfront payment, royalties and various regulatory and sales-based milestones payments to Stempeutics will be committed by Alkem.

Stempeutics has successfully completed a phase II clinical trial of Stempeucel in India. The trial outcomes have been published in the peer-reviewed indexed journal Arthritis Research & Therapy, UK.

Stempeucel is expected to be available in Indian market by 2020 after undergoing the Phase 3 clinical trial in India, which is expected to commence in 2018.